NCT06311851View on ClinicalTrials.gov

Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
CancerMetastatic CancerLiver Metastases
Interventions
DRUG

Bevacizumab

Infusion of Bevacizumab-loaded hepaspher through transarterial chemoembolization.

Trial Locations (1)

021

Pardis Noor Medical Imaging and Cancer Center, Tehran

All Listed Sponsors
lead

Pardis Noor Medical Imaging and Cancer Center

OTHER